ArticleTranslational cancer research2022
Prognostic risk factors for T1 thoracic esophageal cancer: a retrospective cohort study.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer has a poor overall prognosis and a high incidence of post-treatment complications. This study aimed to analyze the common surgical methods for treating T1 thoracic esophageal cancer and explore its prognostic risk factors to provide a basis for appropriate treatment selection. Methods: In this population-based retrospective cohort study, data of patients diagnosed with T1 thoracic esophageal cancer from 2010 to 2016 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided according to those who had surgery and those who had radiotherapy. Survival curves were generated using the Kaplan-Meier method and validated by the log-rank test. Cox's regression model was used to analyze the independent prognostic risk factors. Results: Overall, 2,027 eligible patients, including 824 and 1,203 patients in the surgical and non-surgical groups, respectively, were analyzed. There was no significant difference in survival between the surgical and non-surgical groups (P=0.79). In subgroup analysis, the Cox regression analysis showed that radiotherapy was a significant prognostic factor (P=0.00059). Conclusions: The impact of surgery on patients with T1 thoracic esophageal cancer was insignificant; however, radiotherapy was an independent prognostic risk factor. These results provide a reliable basis for clinical treatment of patients with T1 thoracic esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.